# Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Source: https://onco.cc/trials/nct06050317/  
OnCo record `nct06050317` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Shandong Cancer Hospital and Institute, now recruiting.

## Summary

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer is a phase 2, interventional study registered as NCT06050317 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 25 participants, started 2023-08-18 and due to reach its primary completion in 2025-08-18. Interventions recorded: Sintilimab Plus mFFN or NALIRIFOX and Radiation. Conditions listed: Pancreas Cancer. Primary outcome: PFS; AE. Pancreatic eligibility wording from the registry: "* Pathological tissue-confirmed unresectable locally advanced pancreatic cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06050317
- Phase: 2
- Setting: Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial
- Sponsor: Shandong Cancer Hospital and Institute
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06050317: https://clinicaltrials.gov/study/NCT06050317

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06050317.json